Supplemental material
Review
Trends in industrialization of biotherapeutics: a survey of product characteristics of 89 antibody-based biotherapeutics
Kyle P. Martina Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USA
https://orcid.org/0000-0001-6946-4813View further author information
https://orcid.org/0000-0001-6946-4813View further author information, Christine Grimaldib Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USAhttps://orcid.org/0000-0002-5915-4317View further author information
https://orcid.org/0000-0002-5915-4317View further author information, Rolf Gremplerc Clinical Pharmacology, Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USAhttps://orcid.org/0000-0002-9291-4947View further author information
https://orcid.org/0000-0002-9291-4947View further author information, & Sandeep Kumara Biotherapeutics Discovery, Boehringer Ingelheim Pharmaceutical Inc, Ridgefield, CT, USACorrespondence[email protected]
https://orcid.org/0000-0003-2840-6398View further author information
https://orcid.org/0000-0003-2840-6398View further author information